Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2025 08:00 ET | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

BlossomHill Therapeutics, Inc. today announced the first patient dosed in the expansion cohorts of the SOLARA trial, the first-in-human trial of BH-30643.